AbbVie’s top job today centers on developing new sources of revenue out of the fear that biosimilars to its megablockbuster Humira will cause a precipitous sales decline starting in 2023. But after analyzing prior cases, one team of analysts believes Humira might experience a more graceful fall than pharma watchers currently expect.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,